Skip to main content
. Author manuscript; available in PMC: 2023 Jun 24.
Published in final edited form as: Pharmacol Ther. 2022 Oct 22;240:108300. doi: 10.1016/j.pharmthera.2022.108300

Table 8:

Nanocarriers for Gemcitabine Delivery into Cancer Cells

Nanomedicine Ingredient Cell system Reference
Nanoparticles PLGA, Chitosan, BSA, Soy lecithin, GMS, Tween 20, PLGA-b-PEG-OH, Stearic acid, Squalene, Lipid bilayer-MSNP Panc-1, MIA PaCa-2, AsPc-1, CEM-AraC-8C, CEM-AraC-8D, L1210R (Arya, Vandana, Acharya, & Sahoo, 2011; Chung, Sandoval, Sloat, Lansakara, & Cui, 2012; Cosco, et al., 2012; Daman, Ostad, Amini, & Gilani, 2014; Hung, et al., 2015; Lansakara, Rodriguez, & Cui, 2012; J. Li, et al., 2013; Meng, et al., 2015; Papa, et al., 2012; Reddy, et al., 2007; Sloat, et al., 2011; Wonganan, et al., 2013)
Nanoassemblies Ethanol, aqueous dextrose solution Panc-1, L1210 10K cells (Maksimenko, Caron, Mougin, Desmaele, & Couvreur, 2015)
Liposomes DPPC, Chol, DSPE-PEG2000, DOPE, CHEMS, DSPE-mPEG2000 MDA-MB-231 breast cancer cells, MIA PaCa-2 (Papa, et al., 2013; Y. Xu & Meng, 2016)
Micelles PEG-PLA, Stearic acid, PEG-PCC, Stearoyl-PEG AsPc-1, MIA PaCa-2 (Chitkara, Mittal, Behrman, Kumar, & Mahato, 2013; Daman, et al., 2014; Papa, et al., 2012; Zhu, Budin, & Szostak, 2013)